Who are Sumatriptan and Naproxen sodium's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sumatriptan-and-naproxen-sodium.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Sumatriptan and Naproxen sodium — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sumatriptan and Naproxen sodium (Sumatriptan and Naproxen sodium) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triptan/NSAID combination. Area: Neurology.

marketed Triptan/NSAID combination 5-HT1B/1D receptors (sumatriptan); COX-1/COX-2 (naproxen sodium) Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Sumatriptan and Naproxen sodium (Sumatriptan and Naproxen sodium) — POZEN. Sumatriptan activates serotonin 5-HT1B/1D receptors to relieve migraine pain, while naproxen sodium inhibits cyclooxygenase enzymes to reduce inflammation and provide additional analgesic effect.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Sumatriptan and Naproxen sodium TARGET	Sumatriptan and Naproxen sodium	POZEN	marketed	Triptan/NSAID combination	5-HT1B/1D receptors (sumatriptan); COX-1/COX-2 (naproxen sodium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triptan/NSAID combination class)

POZEN · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Sumatriptan and Naproxen sodium — Competitive Intelligence Brief. https://druglandscape.com/ci/sumatriptan-and-naproxen-sodium. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab